MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

The Medicines Company Company Profile (NASDAQ:MDCO)

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (?)
Ratings Breakdown: 3 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $46.89 (24.67% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2016Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016OppenheimerReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016Chardan CapitalBoost Price TargetBuy$50.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015RBC CapitalBoost Price TargetOutperform$46.00 -> $48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Piper JaffrayReiterated RatingNeutral$28.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015GuggenheimBoost Price Target$42.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Citigroup Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014Credit SuisseUpgradeNeutral -> Outperform$27.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2014Bank of AmericaLower Price TargetBuy -> Neutral$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/1/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha